{"entity":{"id":"ileukon-therapeutics","kind":"company","name":"iLeukon Therapeutics","aka":["iLeukon Therapeutics, Inc.","Cytimm Therapeutics"],"tldr":"iLeukon Therapeutics makes ILKN421H, an mRNA medicine given into a vein that makes the body produce a modified form of interleukin-2, an immune signal that boosts cancer-killing T cells. It is being tested with pembrolizumab in advanced non-small cell lung cancer.","summary":"iLeukon Therapeutics, Inc., at 6393 Nancy Ridge Road, San Diego, California, is a clinical-stage company developing interleukin-2 based mRNA therapies for cancer; its website also refers to the company as Cytimm, which co-founder Haining Huang is described as co-founding in February 2020 as a spin-off of ACEA Therapeutics' immuno-oncology division. Its lead product ILKN421H is a lipid nanoparticle mRNA drug, given intravenously, that encodes a fusion of human serum albumin with a non-alpha IL-2 variant that binds IL-2 receptor beta and gamma but not alpha, intended to activate CD8 T cells and NK cells without expanding regulatory T cells. The company says investigator-initiated trials of ILKN421H alone or with pembrolizumab began in 2023 (first in human in August 2023), and its pipeline lists a US IND with a phase 2 protocol for ILKN421H plus pembrolizumab in first-line and post-immunotherapy non-small cell lung cancer (October 2025) and a combination with a CD19 in vivo CAR-T. Its first registered cancer trial, NCT07452224, a phase 2 study of ILKN421H with pembrolizumab in advanced NSCLC, was posted on ClinicalTrials.gov in March 2026. Its chairman, Henry Ji, co-founded Sorrento Therapeutics.","asOf":"2026-10-29","links":[{"label":"Official website","url":"http://www.ileukon.com/"},{"label":"ClinicalTrials.gov: phase 2 trial of ILKN421H plus pembrolizumab in advanced NSCLC (NCT07452224)","url":"https://clinicaltrials.gov/study/NCT07452224"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":["il2rb","il2rg"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07452224"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not recorded: the website describes a co-founder founding Cytimm Therapeutics in February 2020, but does not state when iLeukon itself was formed or confirm that the two are the same entity.","The registry contact domain is cytimm.com, which did not serve readable content; the iLeukon website renders with JavaScript and was read from its application code.","Earlier investigator-initiated trials described by the company were not found in the registry data read.","No financing round was found; none is recorded.","Company website read on 29 October 2026."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"http://www.ileukon.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/ileukon-therapeutics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"target":[{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/"},{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/"}],"trial":[{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/"}]}}